Hiv

Medications in the "Hiv" category are antiretroviral drugs used to treat human immunodeficiency virus infection and to reduce the risk of virus-related complications. These medicines work by interrupting stages of the virus life cycle, lowering the amount of virus in the blood and helping the immune system recover or remain stable. The category covers single agents, fixed-dose combinations and formulations intended for long-term suppression of viral replication as part of antiretroviral therapy (ART).

Common uses include long-term management of established HIV infection, initiation of first-line or later-line ART regimens, and sometimes short-term use for exposure prevention in specific clinical situations. Treatments in this class are also used in patients with coexisting viral infections when certain drugs have activity against both viruses. Therapy is typically organized to achieve durable viral suppression, limit immune damage, and reduce the chance of onward transmission.

Medications found in this category span several drug classes. Examples of individual products that are often encountered include Epivir and Epivir HBV, Kaletra and Sustiva. Epivir is an agent that has been used in HIV care, while Epivir HBV is a related formulation with use in hepatitis B in many markets. Kaletra is a combination protease inhibitor formulation, and Sustiva is an example of a non-nucleoside reverse transcriptase inhibitor (NNRTI). Other products in the broader category include nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), integrase strand transfer inhibitors (INSTIs), entry inhibitors and additional protease inhibitors and combination tablets designed to simplify dosing.

How these medicines are commonly used reflects modern treatment principles: drugs are usually prescribed in combinations to increase effectiveness and reduce the chance of resistance, and many regimens are taken daily in tablet form. Some patients receive single-tablet regimens that combine several active agents, while others follow multi-pill schedules tailored to prior treatment history or coexisting conditions. The overall therapeutic aim is sustained viral suppression and preservation of immune function rather than short-term symptom relief.

General safety considerations include the potential for drug-specific side effects and interactions with other medicines. Side effects reported across different antiretroviral agents range from mild gastrointestinal symptoms and headache to sleep disturbances or metabolic changes, depending on the exact drug. Certain drug classes are more likely to affect liver function or lipid metabolism, and others interact with widely used medicines through liver enzymes. Laboratory monitoring and assessment of tolerability are commonly part of standard care for people on antiretroviral regimens.

When choosing a medicine from this category, people typically weigh effectiveness at suppressing viral load, the known side-effect profile, the convenience of dosing, compatibility with other conditions or concomitant medications, and whether a fixed-dose combination is available. Formulation options (tablets, combination pills), stability during travel, and regulatory status or availability in a given country are also frequent considerations. As these products are prescription therapies, selection is generally influenced by prior treatment history, coexisting infections or conditions, and supply or reimbursement arrangements in a person’s health system.